Solid Biosciences, Inc. (SLDB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.25-1.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SLDB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -46.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SLDB — debt issuance
Dated 2026-08-06
Other Events. On August 6, 2026, Solid Biosciences Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) under the Company’s universal shelf registration statement on Form S-3 (File No. 333-287325) that was originally filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2025 and was declared effective by the SEC on May 27, 2025 (the “Registration Statement”), relating to the offer and sale of a total of up to $200.0 million of shares of the Compa…
Why it matters: Funding updates matter. They help keep operations going until 2028. They also affect finances.
Supportive ifThe private placement was successful. It raised at least $200 million.
Worry ifFailure to secure the planned funding or a delay in the private placement process.
Why it matters: The private placement details will show how the company can fund its work until 2028. This affects its financial stability.
Supportive ifA press release will explain the private placement's completion and how much money was raised.
Worry ifThere is no news or delays about the private placement funding.
Why it matters: A drop in sector revenue growth may show wider problems for Solid Biosciences.
Worry ifSector revenue growth is reported below its usual median.
Less concerning ifSector revenue growth is still above its usual median.
Why it matters: Trends in cash burn will indicate how well the company is managing its finances. High cash burn could raise concerns.
Worry ifCash burn from operations is lower than in previous quarters.
Less concerning ifCash burn from operations is higher or stays the same compared to previous quarters.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$304 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $765 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,859 loss on $10,000 · 38.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on the SGT-003 trial will show if the company is advancing its key product. Positive news could boost investor confidence.
Supportive ifA press release announcing further positive interim results from the SGT-003 trial.
Worry ifNo updates or negative results from the SGT-003 trial.
Why it matters: Losing more money could mean bigger financial problems. This affects investor trust and future funding.
Worry ifOperating losses reported worse than -$57.4M in Q2 2026.
Less concerning ifOperating losses reported better than -$57.4M in Q2 2026.
Why it matters: Updates on SGT-003 are key for investor confidence in the product pipeline. Positive data can support the stock.
Supportive ifThere is news of more positive clinical data from the Phase 1/2 INSPIRE DUCHENNE trial.
Worry ifThere is a report of bad clinical trial results or no updates for a long time.
Why it matters: High cash burn raises concerns about financial health. It impacts investor confidence and future funding needs.
Worry ifCash burn from operations reported above $50 million in Q3.
Less concerning ifCash burn from operations reported below $50 million in Q3.